NIH R01 · 2024
Neural mechanisms of psilocybin-assisted treatment for alcohol use disorder.
Preclinical and clinical research provides strong evidence that psilocybin and other 5-HT2A agonist/partial agonist psychedelics have antiaddictive effects. In a double-blind randomized controlled trial of psilocybin- assisted treatment for alcohol use disorder (AUD), administration of psilocybin resulted in robust decreases in drinking which were sustained for 28 weeks following drug administration. Self-report measures showed that psilocybin treatment was associated with decreased alcohol craving and decreased negative emotionality (NE). Data from an fMRI pilot study in a sub-sample of trial participants (n = 11) showed normalization of response to alcohol cues and negative emotional…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.